Daina Graybosch

“I wonder if you can talk about LightSpark 12, which we'll see at ESMO after that event, and your expectations for PFS and OS from that study. And is there a specific signal that would give you confidence or increase your confidence that CAS can exceed there with AXE and a PD-1 where Bells, Lemva, and Pembro failed?”

“Sorry, I dialed in and it was a little confusing on Zoom. Thank you for the question. Another one on Matisse going into the AACR presentation. If I recall the initial data that Astra generated was in relapsed refractory lung cancer.”

“I wonder, and maybe I'm being presumptuous, but what gives you confidence in a second half launch? Does that assume priority review for FDA for a NIDO cell? And then for your 2027 filing from IMAGINE-3, is that going to be on the MRD endpoint or on a survival endpoint?”

“First, on TIGIT, as you pointed out, the TIGIT Phase 3s are dominated by the EPSI silent, yours, and ASTRA by specific. And let's say we assume, as I think you believe, that EPSI silent is really the key to maximizing TIGIT benefit.”

“I wonder if we can talk about the process to add lenacapivir to the USPSTS mandate for coverage about cost sharing? I'm assuming SCOTUS upholds the constitutionality in June.”